|
Hemato-oncology
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2024;39(3):501-512. Published online January 30, 2024
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL).
Methods: This multicenter prospective cohort study enrolled newly diagnosed pat..
|
|
|
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation
So Yeon Jeon, Ho-Young Yhim, Hee Sun Kim, Jeong-A Kim, Deok-Hwan Yang, Jae-Yong Kwak
Korean J Intern Med. 2018;33(6):1169-1181. Published online January 8, 2018
Background/Aims: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin’s lymphoma (NHL) is limited.
Methods: Consecutive patients with aggressive NHL ..
|
|
|
Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma
So-Yeon Jeon, Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Jae-Yong Kwak, Chang-Yeol Yim
Korean J Intern Med. 2017;32(2):365-368. Published online February 2, 2016
|
|
|
Successful treatment of myelodysplastic
syndrome and Behcet colitis after allogeneic
hematopoietic stem cell transplantation
Min-Ha Kook, Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Hee Sun Kim, Chang-Yeol Yim, Jae-Yong Kwak
Korean J Intern Med. 2014;29(1):123-125. Published online January 2, 2014
|
|
|
Treatment of Diffuse Large B Cell Lymphoma
Jae-Yong Kwak
Korean J Intern Med. 2012;27(4):369-377. Published online November 27, 2012
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in..
|
|
|
